Phio Pharmaceuticals Financials
PHIO Stock | USD 2.44 0.09 3.83% |
The essential information of the day-to-day investment outlook for Phio Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Phio Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Phio Pharmaceuticals.
Net Income |
|
Phio | Select Account or Indicator | Build AI portfolio with Phio Stock |
Phio Pharmaceuticals Stock Summary
Phio Pharmaceuticals competes with Village Super, CDW Corp, Loews Corp, Assurant, and Best Buy. Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Phio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US71880W5013 |
CUSIP | 74979C303 74979C501 71880W303 74979C808 71880W402 71880W204 71880W501 74979C105 |
Location | Massachusetts; U.S.A |
Business Address | 11 Apex Drive, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | phiopharma.com |
Phone | 508 767 3861 |
Currency | USD - US Dollar |
Phio Pharmaceuticals Key Financial Ratios
Gross Profit | (3.67 M) | ||||
EBITDA | (7.12 M) | ||||
Net Income | (7.15 M) | ||||
Total Asset | 5.74 M | ||||
Retained Earnings | (146.36 M) |
Phio Pharmaceuticals Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 15.7M | 25.2M | 12.8M | 9.4M | 5.7M | 5.5M | |
Other Current Liab | 857K | 1.2M | 2.5M | 890K | 942K | 1.3M | |
Net Debt | (13.6M) | (23.8M) | (11.5M) | (8.5M) | (5.4M) | (5.7M) | |
Retained Earnings | (103.6M) | (116.9M) | (128.4M) | (139.2M) | (146.4M) | (139.0M) | |
Accounts Payable | 728K | 283K | 779K | 657K | 253K | 240.4K | |
Cash | 14.2M | 24.1M | 11.8M | 8.5M | 5.4M | 10.4M | |
Other Current Assets | 920K | 670K | 665K | 832K | 354K | 490.2K | |
Total Liab | 2.7M | 3.2M | 2.0M | 1.6M | 1.0M | 964.3K | |
Total Current Assets | 15.2M | 24.7M | 12.4M | 9.3M | 5.7M | 5.4M | |
Short Term Debt | 232K | 250K | 270K | 35K | 31.5K | 29.9K | |
Net Tangible Assets | 13.6M | 5.7M | 13.0M | 21.9M | 25.2M | 26.5M | |
Net Invested Capital | 13.2M | 21.9M | 10.8M | 7.7M | 4.7M | 4.5M | |
Net Working Capital | 13.0M | 21.7M | 10.5M | 7.7M | 4.7M | 4.5M |
Phio Pharmaceuticals Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Operating Income | (8.8M) | (13.5M) | (11.5M) | (10.8M) | (7.4M) | (7.8M) | |
Ebit | (8.9M) | (13.5M) | (11.5M) | (10.8M) | (7.2M) | (7.5M) | |
Research Development | 4.4M | 8.9M | 7.0M | 6.3M | 3.6M | 5.5M | |
Ebitda | (8.7M) | (13.4M) | (11.3M) | (10.6M) | (7.1M) | (7.5M) | |
Income Before Tax | (8.8M) | (13.3M) | (11.5M) | (10.8M) | (7.2M) | (7.5M) | |
Net Income | (8.8M) | (13.2M) | (11.3M) | (10.8M) | (7.2M) | (7.5M) | |
Income Tax Expense | (134.3K) | (75K) | (175K) | 204K | (7.2M) | (6.8M) | |
Gross Profit | (183K) | (192K) | (193K) | (6.3M) | (7.3M) | (7.6M) | |
Cost Of Revenue | 183K | 192K | 193K | 6.3M | 35K | 33.3K |
Phio Pharmaceuticals Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change In Cash | 7.3M | 9.8M | (12.3M) | (3.3M) | (3.1M) | (3.0M) | |
Free Cash Flow | (8.8M) | (11.9M) | (12.3M) | (10.8M) | (7.1M) | (7.5M) | |
Depreciation | 72K | 75K | 193K | 184K | 35K | 33.3K | |
Other Non Cash Items | 111K | 117K | 496.0 | 126K | (6K) | (5.7K) | |
Capital Expenditures | 72K | 19K | 51K | 121K | 1K | 950.0 | |
Net Income | (8.8M) | (13.3M) | (11.5M) | (10.8M) | (7.2M) | (7.5M) | |
End Period Cash Flow | 14.3M | 24.1M | 11.8M | 8.5M | 5.4M | 10.5M | |
Investments | (72K) | (19K) | (51K) | (121K) | 8K | 8.4K | |
Change To Netincome | 282K | 409K | 247K | 364K | 327.6K | 542.3K |
Phio Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Phio Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Phio Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Phio Pharmaceuticals competition to find correlations between indicators driving Phio Pharmaceuticals's intrinsic value. More Info.Phio Pharmaceuticals Corp is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Phio Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Phio Pharmaceuticals Corp Systematic Risk
Phio Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Phio Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-one with a total number of output elements of fourty. The Beta measures systematic risk based on how returns on Phio Pharmaceuticals Corp correlated with the market. If Beta is less than 0 Phio Pharmaceuticals generally moves in the opposite direction as compared to the market. If Phio Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Phio Pharmaceuticals Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Phio Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Phio Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Phio Pharmaceuticals July 1, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Phio Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Phio Pharmaceuticals Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Phio Pharmaceuticals Corp based on widely used predictive technical indicators. In general, we focus on analyzing Phio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Phio Pharmaceuticals's daily price indicators and compare them against related drivers.
Downside Deviation | 6.37 | |||
Information Ratio | 0.1258 | |||
Maximum Drawdown | 71.2 | |||
Value At Risk | (11.31) | |||
Potential Upside | 18.6 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.